EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment.

@article{Brugger2012EGFRTKIRN,
  title={EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment.},
  author={W. E. Brugger and Michael Thomas},
  journal={Lung cancer},
  year={2012},
  volume={77 1},
  pages={2-8}
}
Treatment with receptor-tyrosine kinase inhibitors (TKIs) has improved progression-free and overall survival in patients with advanced non-small cell lung cancer (NSCLC). One major target for treatment with TKI is the epidermal growth factor receptor (EGFR), particularly in patients harboring activating mutations. However, despite initial responses and long lasting remissions, the development of secondary resistance inevitably leads to treatment failure. Analyzing recent data from various phase… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…